Monopar Therapeutics (MNPR) Interest Expenses (2016 - 2026)
Monopar Therapeutics (MNPR) posted Interest Expenses of $22089.0 for Q4 2025, down 80.06% sequentially from $110800.0 in Q3 2025, and down 99.88% YoY from $17.9 million in Q4 2024.
Monopar Therapeutics (MNPR) Interest Expenses (2016 - 2026) Analysis & Trends
Monopar Therapeutics has reported Interest Expenses for 10 years, with the latest figure at $22089.0 in Q4 2025.
- Quarterly Interest Expenses fell 99.88% year-over-year to $22089.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22089.0 (down 99.88% YoY) and the FY2025 annual result came in at $22.2 million, up 24.46% from the prior year.
- Interest Expenses declined to $22089.0 in Q4 2025 per MNPR's latest filing, from $110800.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $17.9 million in Q4 2024 and troughed at $4.0 in Q1 2025.
- A 5-year average of $4.6 million and a median of $110800.0 in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2021 and 2025: Interest Expenses jumped 47.89% in 2021, then tumbled 99.88% in 2025.
- Over 5 years, Interest Expenses stood at $7.7 million in 2021, then soared by 44.32% to $11.1 million in 2022, then rose by 19.07% to $13.3 million in 2023, then surged by 34.72% to $17.9 million in 2024, then sank by 99.88% to $22089.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $22089.0, $110800.0, and $124090.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 220,489.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220,489.00 |
| Jun 30, 2026 | 220,489.00 |
| Dec 31, 2025 | 22,089.00 |
| Dec 31, 2025 | 22,089.00 |
| Sep 30, 2025 | 110,800.00 |
| Sep 30, 2025 | 110,800.00 |
| Jun 30, 2025 | 124,090.00 |
| Jun 30, 2025 | 124,090.00 |
| Mar 31, 2025 | 4.00 |
| Mar 31, 2025 | 4.00 |
| Dec 31, 2024 | 17.87 Mn |
| Dec 31, 2024 | 17.87 Mn |
| Dec 31, 2023 | 13.27 Mn |
| Dec 31, 2023 | 13.27 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Dec 31, 2022 | 11.14 Mn |
| Sep 30, 2022 | 3,395.00 |
| Sep 30, 2022 | 3,395.00 |
| Jun 30, 2022 | 84,760.00 |
| Jun 30, 2022 | 84,760.00 |